Clinical trials
Completed Phase 2 trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,267 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 15 |
| 2001 | 13 |
| 2002 | 28 |
| 2003 | 33 |
| 2004 | 48 |
| 2005 | 39 |
| 2006 | 47 |
| 2007 | 52 |
| 2008 | 65 |
| 2009 | 57 |
| 2010 | 60 |
| 2011 | 69 |
| 2012 | 57 |
| 2013 | 48 |
| 2014 | 59 |
| 2015 | 84 |
| 2016 | 75 |
| 2017 | 73 |
| 2018 | 51 |
| 2019 | 63 |
| 2020 | 52 |
| 2021 | 57 |
| 2022 | 42 |
| 2023 | 26 |
| 2024 | 18 |
| 2025 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 1,267 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 90 |
| GlaxoSmithKline | 58 |
| European Organisation for Research and Treatment of Cancer - EORTC | 52 |
| Radboud University Medical Center | 45 |
| Bayer | 42 |
| Boehringer Ingelheim | 40 |
| Hoffmann-La Roche | 38 |
| AstraZeneca | 36 |
| Bristol-Myers Squibb | 30 |
| Sanofi | 30 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 54 |
| Pulmonary Disease, Chronic Obstructive | 39 |
| Neoplasms | 32 |
| Breast Neoplasms | 29 |
| Heart Failure | 28 |
| Colitis, Ulcerative | 25 |
| Crohn Disease | 24 |
| Asthma | 22 |
| Alzheimer Disease | 21 |
| Diabetes Mellitus, Type 2 | 19 |
Trials
Showing 1 to 25 of 1,267. Each trial links to its page on Pharma Observatory.
1,167 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.